MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.

$14.97  -0.45 (-2.92%)
As of 05/10/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2017
Outstanding shares:  69,051,438
Average volume:  538,407
Market cap:   $1,029,556,941
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    59045L106
ISIN:        US59045L1061
Sedol:      BF3NP05
Valuation   (See tab for details)
PE ratio:   -12.09
PB ratio:   4.65
PS ratio:   0.00
Return on equity:   -38.60%
Net income %:   -10,620.39%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy